Immune Thrombocytopenia Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 28, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 2.45 billion |
|
Revenue Forecast in 2030 |
US$ 3.93 billion |
|
CAGR |
5.4% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Type, Therapy, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global immune thrombocytopenia therapeutics market was valued at US$ 2.45 billion in 2021 and is expected to register a revenue CAGR of 5.4% to reach US$ 3.93 billion by 2030.
Immune Thrombocytopenia Therapeutics Market Fundamentals
Immune thrombocytopenia (ITP), also known as immunological thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune condition occurring when the body destroys its platelets and decimates them too quickly. ITP is a condition that affects blood platelet number rather than function. Many ITP symptoms are caused by excessive bleeding from a low platelet count. Anemia, which can cause fatigue and impede reaction to activity, can develop in severe cases due to frequent bleeding episodes. Intracranial hemorrhage, which causes significant bleeding into the brain, can occasionally happen. ITP can affect anyone at any age, from 3 months to over 100. ITP is identified in patients under the age of 10 in about 40% of cases. Males and females are equally affected until adolescence, with the frequency being highest between the ages of 2 and 4. Females are more likely to develop ITP between adolescence and 60 years of age. Adults over 60 years had the highest frequency of the disease.
Acute (short-term) and chronic immunological thrombocytopenia are the two basic kinds of ITP. It is divided into primary and secondary categories based on the underlying cause of the condition. Primary ITP is defined as immune-mediated thrombocytopenia without other underlying causes or disorders that may be related to thrombocytopenia. In contrast, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced or related to systemic illness (Such as systemic lupus erythematosus, infection [for instance, HIV], immune deficiency [for instance, common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
The main objective of treatment for ITP is to increase platelet count to stop significant bleeding. ITP is managed in various ways, and current international recommendations suggest several first- and second-line alternatives, including some medications that have not received EU approval for this particular illness. First-line therapeutic choices include corticosteroids, intravenous immunoglobulin (IVIG), and intravenous anti-D immunoglobulin.
The second-line pharmacological therapy includes immunosuppressants cyclophosphamide, azathioprine, cyclosporine or mycophenolate mofetil, large doses of dexamethasone or methylprednisolone, high doses of IVIG or anti-D Ig, vinca alkaloids and danazol, and the anti-CD-20 monoclonal antibody rituximab.
[785668]
Immune Thrombocytopenia Therapeutics Market Dynamics
The demand for ITP therapeutics is expected to increase due to the rising prevalence of ITP worldwide. According to research released by the National Organization for Rare Disorders (NORD), ITP is thought to affect over 200,000 individuals worldwide. Global acceptability of treatments is anticipated to be driven by rising rates of both acute and protracted chronic immunological thrombocytopenia during the projection period. Moreover, the growing patient and healthcare professional awareness of healthcare and uncommon diseases is expected to favorably influence the immune thrombocytopenia market revenue growth. Non-governmental organizations, such as the Immune Thrombocytopenia Support Society and the Platelet Disorder Support Association, are actively involved in educating the public about rare blood illnesses. These initiatives by non-governmental organizations are anticipated to increase the awareness and demand for ITP medications.
The global immune thrombocytopenia therapeutics market is also anticipated to grow due to the increased uptake of combination therapies. Studies have demonstrated that combination therapy has higher patient response rates, cost-effectiveness, and fewer adverse effects. Rituximab with dexamethasone, corticosteroids and IVIG, TPO-RA (eltrombopag), and dexamethasone are some notable combinations of treatments.
However, treatment options for ITP come with various side effects. Corticosteroid side effects include vomiting, nausea, and many others that can result from excessive usage. These factors hamper the global immune thrombocytopenia therapeutics market revenue growth. Also, the high cost of these agents inhibits market revenue growth.
Immune Thrombocytopenia Therapeutics Market Ecosystem
The global immune thrombocytopenia therapeutics market has been analyzed from four perspectives: type, therapy, distribution channel, and region.
Immune Thrombocytopenia Therapeutics Market by Type
[8657567]
Based on type, the global immune thrombocytopenia therapeutics market has been segmented into acute immune thrombocytopenia and chronic immune thrombocytopenia.
The chronic immune thrombocytopenia segment is estimated to capture a dominant market revenue share. The lack of options in the second line of treatment is estimated to lead to increase in the adoption of thrombopoietin receptor agonists. It is further expected to drive the growth of this segment. Moreover, the chronic immune thrombocytopenia segment is likely to lose its market share due to the high cost associated with the treatment and the possible launch of biosimilars.
Immune Thrombocytopenia Therapeutics Market by Therapy
Based on therapy type, the global immune thrombocytopenia therapeutics market has been segmented into intravenous immunoglobulin (IVIG), corticosteroids, anti-D immunoglobulin, thrombopoietin receptor agonist (TPO-RA), and others.
The intravenous immunoglobulins (IVIG) segment is anticipated to grow at a faster revenue CAGR in the global immune thrombocytopenia therapeutics market during the forecast period. This can be attributed to the growing need for IVIGs in order to treat and manage ITP. Furthermore, the expected patent expiration of key thrombopoietin receptor agonist (TPO-RA) branded medications by the end of 2022 is likely to lower the cost of second-line therapy, resulting in a fall in the market value of the pharmacological class. The corticosteroids segment accounts for a considerable revenue share of the global immune thrombocytopenia therapeutics market due to their widespread usage and cost-effectiveness.
Immune Thrombocytopenia Therapeutics Market by Distribution Channel
Based on the distribution channel, the global immune thrombocytopenia therapeutics market has been segmented into hospital pharmacies, retail pharmacies, and others (including online pharmacies).
The hospital pharmacy segment accounts for the largest revenue share of the global immune thrombocytopenia therapeutics market. This results from increased usage of IVIG and TPO-RA treatments for ITP. In addition, a rise in the usage of rescue therapy in hospitals is caused by a higher frequency of bleeding disorders in people with ITP. Hospital pharmacies can also dominate the ITP market due to this feature.
Immune Thrombocytopenia Therapeutics Market by Region
Based on the region, the global immune thrombocytopenia therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounts for a significant revenue share in the immune thrombocytopenia therapeutics market. It is anticipated to emerge as a dominant region during the forecast period. This is attributed to factors such as improved access to ITP therapy, increased market share for major companies, sophisticated healthcare infrastructure, and growth in the public awareness of rare blood disorders. Additionally, an increase in the availability of infrastructure facilities and higher investments in developing novel therapeutic molecules for the management of ITP in North America is expected to significantly boost the adoption of ITP treatment in the region.
Immune Thrombocytopenia Therapeutics Market Competitive Landscape
The prominent players operating in the global immune thrombocytopenia therapeutics market are:
Immune Thrombocytopenia Therapeutics Market Strategic Developments
The global immune thrombocytopenia therapeutics market is expected to register growth at a revenue CAGR of 5.4% during the forecast period from 2022 to 2030.
Amgen Inc., Novartis AG, Octapharma AG, Saol therapeutics, and CSL Behring Ltd. are among the key players in the global immune thrombocytopenia therapeutics market.
The intravenous immunoglobulin (IVIG) segment dominates the global immune thrombocytopenia therapeutics market.
Asia Pacific is expected to observe the highest revenue growth in the immune thrombocytopenia therapeutics market during the forecast period.
The global immune thrombocytopenia therapeutics market was valued at US$ 3.93 billion in 2021.
*Insights on financial performance are subject to the availability of information in the public domain